Russell Investments Group Ltd. Purchases 20,416 Shares of GRAIL, Inc. $GRAL

Russell Investments Group Ltd. increased its position in GRAIL, Inc. (NASDAQ:GRAL) by 255.6% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 28,403 shares of the company’s stock after acquiring an additional 20,416 shares during the quarter. Russell Investments Group Ltd.’s holdings in GRAIL were worth $1,939,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the business. N.E.W. Advisory Services LLC bought a new stake in GRAIL during the 4th quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd acquired a new position in GRAIL in the 4th quarter valued at approximately $28,000. Elyxium Wealth LLC bought a new stake in GRAIL in the fourth quarter worth approximately $31,000. Comerica Bank increased its holdings in GRAIL by 59.2% in the third quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after purchasing an additional 173 shares in the last quarter. Finally, Fifth Third Bancorp increased its holdings in GRAIL by 15,733.3% in the first quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock worth $25,000 after purchasing an additional 472 shares in the last quarter.

Insider Activity at GRAIL

In other news, insider Andrew John Partridge sold 1,491 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $61.08, for a total transaction of $91,070.28. Following the completion of the sale, the insider owned 163,738 shares in the company, valued at $10,001,117.04. The trade was a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.83% of the stock is currently owned by corporate insiders.

GRAIL Price Performance

Shares of GRAL opened at $67.87 on Friday. GRAIL, Inc. has a one year low of $29.95 and a one year high of $118.84. The company has a market cap of $3.03 billion, a PE ratio of -6.96 and a beta of 3.24. The stock has a 50-day moving average of $67.58 and a 200-day moving average of $65.35.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.66) by $0.10. The business had revenue of $44.69 million for the quarter, compared to the consensus estimate of $42.39 million. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%. Analysts expect that GRAIL, Inc. will post -10.41 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

GRAL has been the topic of a number of research analyst reports. TD Cowen restated a “buy” rating on shares of GRAIL in a report on Wednesday, July 15th. Mizuho lifted their price objective on shares of GRAIL from $58.00 to $65.00 and gave the company a “neutral” rating in a research note on Wednesday, July 15th. Wolfe Research started coverage on shares of GRAIL in a research report on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a research report on Friday, July 17th. Finally, Wall Street Zen raised shares of GRAIL from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $67.78.

GRAIL Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.